Navigation Links
Equity Research Firm Issued Unauthorized Report and Press Release on Immunosyn Corporation Today
Date:1/16/2008

LA JOLLA, Calif., Jan. 16 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) did not authorize or endorse the release of an Equity Research Profile on the company issued by Proteus Equity Research Partners, a privately-held equity research company, nor the associated press release announced earlier today.

Further, The Blaine Group is the only authorized public and investor relations firm retained by Immunosyn Corporation at this time.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS). (For more information on Immunosyn and SF-1019 go to http://www.immunosyn.com)

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Immunosyn Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Private Equitys Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference
2. MB Software Corporation Reaches Agreement with Keystone Equity Partners
3. Private Equity Firms Acquire American Laser Centers
4. Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock
5. Health Fitness Announces Non-Cash Adjustment and Restatement of 2006 Equity Investment Transaction Resulting in Delay for Filing Third Quarter Form 10-Q
6. Harmony Information Systems Raises $28 Million in Series B Financing from JMI Equity, Updata Partners, ORIX Venture Finance and Comerica Bank
7. StatSure Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR) Review Issued By Scimitar Equity Research, Inc.
8. SEIU Applauds Bipartisan Leadership of Sen. Finance Committee in Push for Greater Oversight of Private Equity Takeovers of Nursing Homes
9. Conseco Completes Divestiture of Old Block of Fixed and Equity-Indexed Annuities
10. Simplex Diabetic Supply, Inc. Secures $50 Million in Growth Equity from New Enterprise Associates
11. With the Largest-Ever Buyout of a National Nursing Home Chain Pending ... New York Times Exposes Harm to Seniors After Private Equity Buyouts of Nursing Homes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... Sam ... insurance assistance, financial planning, and related services to residents of the region, is ... awareness of threatened species and wild lands. , Endangered Species International is committed ...
(Date:3/22/2017)... San Jose, CA (PRWEB) , ... March 22, ... ... of San Jose, Santa Cruz and Milpitas with a robust, ongoing community enrichment ... Supportive Housing (FSH), a nonprofit organization which has provided for the critical needs ...
(Date:3/22/2017)... ... 2017 , ... The American Society for Preventive Cardiology ... for prescribers to improve patients’ access to the revolutionary therapy for appropriate patients ... of the article entitled “PCSK9 Inhibitor Access Barriers: Issues and Recommendations: Improving ...
(Date:3/22/2017)... ... March 22, 2017 , ... Old School Labs™, makers of ... Theophane as a new Brand Ambassador. Theophane, who trained with Floyd Mayweather, made his ... 2011. He has racked up an impressive number of wins in contests in Britain, ...
(Date:3/22/2017)... Georgia (PRWEB) , ... March 22, 2017 , ... ... time consuming and frustrating and this tool bypasses that. Healthcare facilities across ... identified an opportunity to offer their clients and hospitals, across the country, an ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... RADNOR, Pennsylvania , 22 de marzo de ... proveedor independiente global líder de soluciones de productos ... ha anunciado hoy que ha adquirido EPL Archives, ... apoya a los clientes en todo el ciclo ... y comercialización ofreciendo una muestra de archivo, almacenamiento ...
(Date:3/22/2017)... DUBLIN , Mar. 22, 2017 Research ... Care Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 10.9% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/22/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... solutions, today reported financial and operational results for ... 31, 2016. 2016 Highlights ... compared to the full year 2015  ... year  Direct-to-consumer model launched in ...
Breaking Medicine Technology: